AMD

DVCon U.S. 2024 Announces Stuart Sutherland Best Paper & Best Poster Winners & Conference Highlights

Retrieved on: 
Tuesday, March 19, 2024
Shift, Infineon Technologies, Algorithm, Conference, Nvidia, UVM, Lens, PSS, Working Group, DoubleTree, Verification, Ford Motor Company, Human, Formal, Accellera, Functional, Texas Instruments, Exhibition, Paper, Cadence Design Systems, Poster, AMD, Automotive industry

The 2024 Best Paper and Poster winners, as voted on by attendees, were announced during a reception in the exhibit hall on March 6.

Key Points: 
  • The 2024 Best Paper and Poster winners, as voted on by attendees, were announced during a reception in the exhibit hall on March 6.
  • Overall attendance for DVCon U.S. 2024 was approximately 975, including attendees from 25 exhibiting companies.
  • “It was really an exciting time to be back at DVCon U.S.,” stated Tom Fitzpatrick, DVCon U.S. 2024 General Chair.
  • For the second consecutive year, the Poster Ninja Warrior Session determined the Stuart Sutherland Best Poster Award winners.

Nano Dimension Announces Another Deep Learning AI Patent Granted to its DeepCube Technology

Retrieved on: 
Tuesday, March 19, 2024
Intel, Artificial neural network, Patent, Artificial intelligence, AI, Software, Confidentiality, AMD, 3D printing, Data

Waltham, Mass., March 19, 2024 (GLOBE NEWSWIRE) --  Nano Dimension Ltd. (Nasdaq: NNDM) (“Nano Dimension” or the “Company”), a leading supplier of Additively Manufactured Electronics (“AME”) and multi-dimensional polymer, metal & ceramic Additive Manufacturing (“AM”) 3D printing solutions, today announced that a patent was granted for technology developed by its industrial artificial intelligence (“AI”) group, DeepCube, that enables better training and optimization of decentralized deep learning-based AI models.

Key Points: 
  • The new patent addresses this challenge by ultimately training and improving the AI models on customers’ premises, without Nano Dimension having direct access to the new data or model.
  • This patent is another key component in Nano Dimension’s efforts to transform DeepCube from a solely in-house AI group to a leading industrial AI solution provider.
  • Nano Dimension’s DeepCube alone has 50 patent applications filed, of which 27 have already been granted.
  • Yoav Stern, Chief Executive Officer and Member of the Board of Directors of Nano Dimension, stated: “Nano Dimension’s leadership in AI continues to make progress.

AMD Adaptive Computing Technology Powers Sony Semiconductor Solutions LiDAR Automotive Reference Design

Retrieved on: 
Tuesday, March 19, 2024
SSS, Socs, Sony, Perception, Depth perception, ABI, 3D, AI, Field-programmable gate array, Graphics processing unit, Safety, Ozone, AMD, Lidar, Central processing unit, Silicon, Weather, Video game

SANTA CLARA, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Today, AMD (NASDAQ: AMD) announced that its cutting-edge adaptive computing technology was selected by Sony Semiconductor Solutions (SSS) for its newest automotive LiDAR reference design.

Key Points: 
  • SANTA CLARA, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Today, AMD (NASDAQ: AMD) announced that its cutting-edge adaptive computing technology was selected by Sony Semiconductor Solutions (SSS) for its newest automotive LiDAR reference design.
  • Using adaptive computing technology from AMD significantly extends the SSS LiDAR system capabilities, offering extraordinary accuracy, fast data processing, and high reliability for next-generation autonomous driving solutions.
  • “Our collaboration with Sony Semiconductor Solutions integrating AMD adaptive computing technology into its LiDAR reference design exemplifies our dedication to pushing the boundaries of technology and driving innovation in critical industries."
  • "By incorporating AMD adaptive computing technology into our LiDAR reference design, we are poised to set new standards in performance, reliability, and adaptability."

Opthea to Host Key Opinion Leader Event on Sozinibercept (OPT-302) in Wet Age-Related Macular Degeneration on April 3, 2024

Retrieved on: 
Tuesday, March 19, 2024
Retina, University of Nevada, Reno, Houston Methodist Hospital, Webcast, Associate, ASX, KOL, University, Doctor of Philosophy, MBA, University of Illinois Urbana-Champaign, Shore, AMD, FACS, Medicine, Pharmaceutical industry

Additionally, Opthea will provide a strategic outlook.

Key Points: 
  • Additionally, Opthea will provide a strategic outlook.
  • A live question and answer session will follow the formal presentations.
  • To register for this live webcast, click here .
  • A replay of the webcast will be made available on the Company’s website.

Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates

Retrieved on: 
Monday, March 18, 2024
Research, Adverum Biotechnologies, Vasculitis, Three Months, Macula, Chorioretinitis, Inflammation, Patient, Episcleritis, American Academy, Anti-VEGF, LUNA, Intraocular pressure, Investment, Clinical trial, Injection, Safety, Drug development, Paratriathlon, AMD, AAO, OPTIC, Retinitis, CST, Vascular occlusion, Annual general meeting, VEGF, Pharmaceutical industry

REDWOOD CITY, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today reported financial results for the fourth quarter and full year 2023. The company also provided recent pipeline highlights and corporate updates.

Key Points: 
  • The company also provided recent pipeline highlights and corporate updates.
  • 85% and 68% of patients at the 2E11 and 6E10 doses, respectively, received no supplemental injections through 26 weeks.
  • Stock-based compensation expense included in research and development expenses was $1.0 million for the fourth quarter of 2023.
  • Stock-based compensation expense included in general and administrative expenses was $3.1 million for the fourth quarter of 2023.

GraniteShares adds Amazon, AMD, and Microsoft to its 2X leveraged Single-Stock ETFs Lineup

Retrieved on: 
Monday, March 18, 2024
CONL, MSFT, AMD, ETF, AMZN, AUM, Back to the Future, NVDL

NEW YORK, March 18, 2024 (GLOBE NEWSWIRE) -- Today, GraniteShares , an ETF issuer specializing in high conviction ETFs, announced that it has added three new leveraged single-stock ETFs to its existing lineup.

Key Points: 
  • NEW YORK, March 18, 2024 (GLOBE NEWSWIRE) -- Today, GraniteShares , an ETF issuer specializing in high conviction ETFs, announced that it has added three new leveraged single-stock ETFs to its existing lineup.
  • The new ETFs will bring the total number of short and leveraged ETFs that GraniteShares offers to 13.These additions will aim to replicate two times (+2X) the daily variations of their underlying stocks: Advanced Micro Devices (AMD), Amazon (AMZN), and Microsoft (MSFT).
  • As a pioneer in leveraged single-stock ETFs, GraniteShares is committed to continually enhancing its product line to meet evolving customer needs.
  • "Over the last year, we’ve witnessed significant demand for leveraged single-stock ETFs in the U.S. market,” says Will Rhind, Founder and CEO of GraniteShares.

Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer

Retrieved on: 
Monday, March 18, 2024
DAS, Retina, University, Moorfields Eye Hospital, Pathology, Oligonucleotide, Ranibizumab, Data analysis, Partnership, Business, Boehringer Ingelheim, DME, Patient, Pharming, Research, Royal College of Ophthalmologists, Cell biology, Diabetic retinopathy, C3, University College London, MBA, Eye, Johnson & Johnson, Janssen, Drug development, John Radcliffe Hospital, AMD, CLS, University of Oxford, Royal college, Geographic atrophy, Stargardt disease, DMI, Pharmaceutical industry

ALPHARETTA, Ga., March 18, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that Victor Chong, M.D., MBA was appointed Chief Medical Officer on March 14, 2024.

Key Points: 
  • ALPHARETTA, Ga., March 18, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that Victor Chong, M.D., MBA was appointed Chief Medical Officer on March 14, 2024.
  • George Lasezkay, Pharm.D., J.D., President and Chief Executive Officer of Clearside, commented, “Victor is a well-known and well-respected retinal clinician and scientist, who is a strategically focused and visionary leader.
  • We are delighted to have him join the Clearside team.
  • “With the upcoming ODYSSEY data and extensive partnership portfolio, this is an exciting time to join Clearside.

Mercury Announces Early Access Program for New Direct RF Multi-Chip Module Powered by AMD Versal Adaptive SoCs

Retrieved on: 
Monday, March 18, 2024
Failure, AS9100, SIP, GM, SOC, DSP, Documentation, EW, Swap, MRCY, AI, RF, Mercury, Risk, Engineering, Semiconductor, Annual report, Radar, Mercury Systems, AMD, Marketing, Silicon

The RFS1140 is the first multi-chip module to combine the processing power of the AMD Versal® AI Core series adaptive SoC along with Jariet Technologies high-speed data converters and Micron LPDDR4 NOR flash memory.

Key Points: 
  • The RFS1140 is the first multi-chip module to combine the processing power of the AMD Versal® AI Core series adaptive SoC along with Jariet Technologies high-speed data converters and Micron LPDDR4 NOR flash memory.
  • By integrating the latest commercial processing chips into a SWaP-optimized, rugged package, Mercury’s SiP offers maximum performance for next-generation applications.
  • The early access program for the RFS1140 includes product documentation and support as well as priority delivery for evaluation hardware as it becomes available this year.
  • “The Versal AI Core series adaptive SoC coupled with discrete data converters in a single package enables direct RF signal processing capacity with massive DSP and AI compute in a small form factor.

Clearside Biomedical Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, March 12, 2024
Patient, G&A, BioCryst Pharmaceuticals, Eye, Drug delivery, Clinical trial, AAO, Extension, Webcast, Pharming, CPT, Safety, Disease, SPA, American Academy of Ophthalmology, Compass, Insurance, Diabetic retinopathy, Conference call, Aura, AMD, TKI, CLS, FDA, Administration, Conference, SCS, DME, American Academy, OASIS, Injection, Research and development, Axitinib, Pharmaceutical industry

ALPHARETTA, Ga., March 12, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today reported financial results for the fourth quarter and year ended December 31, 2023, and provided a corporate update.

Key Points: 
  • License Revenue: License and other revenue for the fourth quarter of 2023 was $6.3 million, compared to $0.3 million for the fourth quarter of 2022.
  • Research and Development (R&D) Expenses: R&D expenses for the fourth quarter of 2023 were $6.3 million, compared to $5.0 million for the fourth quarter of 2022.
  • General and Administrative (G&A) Expenses: G&A expenses for the fourth quarter of 2023 were $2.9 million, compared to $3.2 million for the fourth quarter of 2022.
  • Other Expense: Non-cash interest expense for the fourth quarter of 2023 was $2.3 million, compared to $2.0 million for the fourth quarter of 2022.

KNIME to Host Annual Spring Summit in Austin, Texas, April 15-17

Retrieved on: 
Friday, April 5, 2024
Professional Services, Data Management, Data Analytics, Technology, Other Technology, Software, Artificial Intelligence, Organization, Conference, Data science, Convention center, Siemens Healthineers, KNIME, AMD, Bird, Machine learning, Tutoring

KNIME , the software company focused on making working with data intuitive, will hold its annual KNIME Spring Summit conference in Austin, Texas, April 15-17, at the AT&T Hotel and Conference Center.

Key Points: 
  • KNIME , the software company focused on making working with data intuitive, will hold its annual KNIME Spring Summit conference in Austin, Texas, April 15-17, at the AT&T Hotel and Conference Center.
  • KNIME Spring Summit offers three days of customer presentations, panels, and on-site trainings and workshops focused on using KNIME software for varying use cases across multiple industries.
  • The onsite training sessions created a momentum that would not have been possible in a virtual setting.
  • Having direct access to peers and trainers is the best way of learning.”
    For those interested in registering for the live or virtual Spring Summit, please visit knime.com/spring-summit-2024 .